Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation : CBD-OH
Sponsor: Assistance Publique - Hôpitaux de Paris
Summary
Randomized clinical trial of 11 days Cannabidiol versus placebo as an adjunctive treatment during inpatient alcohol detoxification to improve abstinence in patients with severe alcohol use disorder.
Official title: Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation in Patients With Severe Alcohol Use Disorder: A Phase II Trial
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
210
Start Date
2024-04-08
Completion Date
2026-05-23
Last Updated
2025-12-03
Healthy Volunteers
No
Conditions
Interventions
Placebo
Placebo made by the same manufacturer to look like the active pills
Half dose CBD
add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 11 days during their inpatient stay
Full dose CBD
add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 11 days during their inpatient stay
Locations (12)
Hôpital Albert Chenevier
Créteil, Albert Chenevier, France
Hôpital Antoine Béclère
Clamart, Clamart, France
CHU Gabriel Montpied
Clermont-Ferrand, Clermont Ferrand, France
Hôpital Louis Mourier
Colombes, Colombes, France
Hôpital Avicenne
Bobigny, France, France
Hôpital Fernand Widal
Paris, France, France
Hôpital Hôtel-Dieu
Paris, Paris, France
Hôpital Cochin
Paris, Paris, France
Hôpital Saint Anne
Paris, Paris, France
Hôpital Bichat
Paris, Paris, France
Hôpital René Muret
Sevran, Sevran, France
Hôpital la Colombière
Montpellier, France